Good morning, everyone, and how are you today? Gray skies are hovering over the Pharmalot corporate campus, where we are firing up the furnace, tending to the mascots and depositng assorted short people at various destinations. Not all at once, though. To cope, yes, we are brewing that trusty - not rusty - cup of stimulation and invite you, as always, to join us. This looks to be another busy day and we need all the fortification we can get. As for you, here are some tidbits. Enjoy your day and stay in touch...
Gilead Scores Win With First Late-Stage Hep C Study (TheStreet)
Merck KGgA Will Not Sell OTC Unit (Reuters)
Cipla Medpro Chief Financial Officer Resigns (Business Day)
Roche Expands Indication For Cervical Cancer Test (Reuters)
The 10 Best Performing Biotech Stocks In 2012 (TheStreet)
Seattle Generics Gets A Boost For Expanding Adcetris (Pharma Times)
Novo Nordisk Claims New Data Show Victoza Has An Advantage (Reuters)
Bayer's Eylea Gets OK In Europe For Wet AMD (Pharma Times)
Poor Adherence Costs Pharma $564 Billion Annually (Pharma Times)
EDITOR'S NOTE: Please check this post for updates